TYK2 inhibition: changing the treatment landscape for psoriasis?

Abrahim Abduelmulaa Faculty of Medicine, University of Western Ontario, London, Ontario, Canada

Melinda J. Gooderhamb Department of Medicine, Queen’s University, Kingston, Ontario, Canada;c Department of Medicine SKiN Centre for Dermatology, Peterborough, Ontario, Canada;d Department of Medicine Probity Medical Research, Peterborough, Ontario, CanadaCorrespondence[email protected]

https://orcid.org/0000-0001-8926-0113

Click to increase image sizeClick to decrease image size

Declaration of interest

M Gooderham has been an investigator, speaker, consultant or advisory board member for AbbVie, Amgen, Akros, Arcutis, Boehringer Ingelheim, BMS, Celgene, Dermira, Dermavant, Galderma, GSK, Eli Lilly, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, UCB, and Valeant/Bausch. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

TYK2 inhibition: changing the treatment landscape for psoriasis?

Information for

Open access

Opportunities

Help and information

TYK2 inhibition: changing the treatment landscape for psoriasis?

Declaration of interest

Reviewer disclosures

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature